# Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

> **NCT00270452** · PHASE1 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 9 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** WT1 and PR1 Peptide Vaccine

## Key facts

- **NCT ID:** NCT00270452
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-22
- **Primary completion:** 2007-10-26
- **Final completion:** 2007-10-26
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270452, "Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00270452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*